INTRATUNNEL THE EFFECT OF ADMINISTRATION OF BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCs) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TENDON-BONE TO INTERFACE HISTOLOGICAL GRAFT ANTERIOR CRUCIATE LIGAMENT APPEARANCE AFTER RECONSTRUCTION IN RABBITS

Atria Abirama¹, Dwikora Novembri Utomo¹², Mouli Edward¹²

¹Department of Orthopaedic, Faculty of Medicine, Airlangga University –Dr. Soetomo Hospital, Surabaya, Indonesia.
²Stem Cell Research and Development Center, Universitas Airlangga Surabaya, East Java, Indonesia.

ABSTRACT

The success of the Anterior Cruciate Ligament (ACL) reconstruction using a tendon graft is determined by integration in the bone tendon-graft interface on the bone tunnel. The use of stem cells and growth factors proved to accelerate the healing of the bone tendon-graft interface. The aim of this study was to investigate the difference of histology picture in the tendon-bone tunnel model after ACL reconstruction with intratunnel intravenous allogenic bone marrow mesenchymal stemcells (BM-MSCs) and intratunnel vascular endothelial growth factor (VEGF). This research used Post-Test Only Control Group design with 20 rabbits divided into treatment group and control group. Each group performed histologic image evaluation (thickness of collagen fiber or sharpey fiber) at week 3 and 6. Evaluation of histology overview at week 3 and week 6 showed a significantly thicker thickness of collagen fiber or sharpey fiber in treatment group compared with control group (p <0.05). Intravenous administration of BM-SCs and VEGF after ACL reconstruction can speed healing of the bone tunnel significantly from week 3 and 6. The study by Faridyan et al has concluded that intravenous BM-SCs + VEGF increased ultimate tension strength in the bone-tendon interface significantly. In this study, intravenous administration of BM-SCs and VEGF gave histologic images showing acceleration of bone tunnel healing.

Keywords: Anterior cruciate ligament reconstruction, allogenic bone marrow mesenchymal stem cells, vascular endothelial growth factor, graft tunnel healing, and Sharpey fiber.

INTRODUCTION

The increase in sports activities will directly increase the incidence of sports injuries. Most sports injuries occur in the knee, and ACL injuries occur in 30-40% of a knee injury. (Baxter et al. 2010). ACL injuries will cause a variety of knee functional impairment due to the anteriorinstability and rotatoryinstability. ACL injuries can also cause injury to the meniscus and cause early osteoarthritis. On ACL injuries, can be given conservative or operative therapy (Alpert et al. 2008). The goal of surgery on ACL reconstruction is to obtain a mechanically stable knee, thereby decreasing the risk of injury to the meniscus and joint surfaces by decreasing anteroposterior joint movement (Myklebust & Bahr 2005).
The main disadvantage of ACL reconstruction using tendon graft is the weak initial linkage in the bone-tendon graft interface. The healing phase between bone-tendon graft in the bone tunnel begins with the formation of fibrovascular tissue between the tendon and bone in the bone-tendon graft interface. This layer will eventually compose fibers perpendicular to each other so as to resemble Sharpey's fibers. The existence and amount of sharpey's fiber is what affects the strength of the fixation between bone-tendon graft (Weiler et al., 2002).

Several studies have shown that the use of Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) in bone tunnel improves the healing of bone-tendon graft in rabbit-bred animals. This is achieved by the formation of perpendicular collagen fibers that connect the tendon to the bone (Sharpey's fibers) and the increased proliferation of cartilage-like cells by week four (Dong et al. 2012; Ma et al. 2007; Ouyang 2004).

The use of growth factor is also proven to accelerate the healing of graft-bone tunnel. BMPs and GFs play a role in the activation and acceleration of bone in growth, collagen fiber synthesis, and fibro cartilaginous differentiation in bone tendon-graft interfaces with the primary goal of achieving bone tendon-graft insertion similar to normal ACL (Milano et al., 2007). Giving Vascular Endothelial Growth Factor (VEGF) increases neovascularization, stimulates fibroblast cell proliferation, collagen synthesis and cell growth in bone tunnels (Deehan & Cawston 2005). The provision of fibrin plugs on the articular side to block the entry of synovial fluid into the bone tunnel and is expected to have a positive effect on the intravenous bone marrow-derived mesenchymal stem cell (BMSCs) + Vascular Endothelial Growth Factor (VEGF) against bone tendon-graft healing. Giving Vascular Endothelial Growth Factor (VEGF) increases neovascularization, stimulates fibroblast cell proliferation, collagen synthesis and cell growth in bone tunnels (Deehan & Cawston 2005). The provision of fibrin plugs on the articular side to block the entry of synovial fluid into the bone tunnel and is expected to have a positive effect on the intravenous bone marrow-derived mesenchymal stem cell (BMSCs) + Vascular Endothelial Growth Factor (VEGF) against bone tendon-graft healing.

Based on the above thought, this research was made to know the difference of histology picture on bone-tendon graft interface after reconstruction of Anterior Cruciate Ligament (ACL) with intratunnel Vascular Endoteric Stem Cells (BMSCs) + Vascular Endothelial Growth Factor (VEGF).

METHODS

This research was a true experimental laboratory study using post-test only control group design. The research unit used New Zealand White Rabbit, male, weighing 3000-4000 gram animals divided into four groups randomly. The number of experimental units for this study is 5 for each his group.
Research was carried out exponentially in the laboratory. The study was divided into 4 groups consisting of 2 (two) treatment groups (P1 and P2), ie the injection of BMSCs + VEGF intratunnel after ACL reconstruction surgery with tendon graft. Evaluation was done at week 3 for P1 group and week 6 for group P2. In 2 (two) control groups (K1 and K2), ie groups without BMSCs + VEGF intratunnel after ACL reconstruction surgery with tendon graft. The evaluation was done at week 3 for K1 group and week 6 for K2 group.

RESULTS
Evaluation of thickness measurement of collagen fiber showed the thickness on treatment group and control group in week 3.

[Graphic 1. The graphic of thickness evaluation of collagen fiber or Sharpey fiber on week 3. It showed the thickness of collagen fiber or Sharpey fiber on control group in week 6 and the thickness of collagen fiber or Sharpey fiber on treatment group in week 6.]

[Figure 2. Histology of collagen fiber or Sharpey fiber, 1. Control the third week; 2. Treatment of the]
The data showed that in the third week, the treatment group using BM-MSCs and VEGF intratunnel had significantly higher collagen fiber or Sharpey fiber thickness than control group (p <0.05)

Table 1. Comparison of the thickness of collagen fiber or sharpey fiber control and treatment groups in the third week.

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>Mean ± SD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5</td>
<td>11.80 ± 5.40</td>
<td>0.006</td>
</tr>
<tr>
<td>Treatment</td>
<td>6</td>
<td>20.50 ± 2.43</td>
<td></td>
</tr>
</tbody>
</table>

After 6 weeks, the study show that there is significant difference between control and treatment group. The treatment group given BM-SCs and VEGF intratunnel, has larger collagen fiber or Sharpey fiber than the control group.

Table 2. Comparison of the thickness of collagen fiber or fiber Sharpey on control groups and treatment groups in 6 weeks treatment.

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>Mean ± SD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5</td>
<td>13.20 ± 4.32</td>
<td>0.039</td>
</tr>
<tr>
<td>Treatment</td>
<td>6</td>
<td>21.67 ± 6.74</td>
<td></td>
</tr>
</tbody>
</table>

Compared to evaluate the thickness of the collagen fiber or Sharpey fiber treatment group at week 3 and week 6, Table 3 does not found significant differences between the two groups (p>0.05)

**DISCUSSION**

This study used a hamstring tendon graft because, it is one of an alternative choice of graft in ACL reconstruction. The success of ACL reconstruction depends on the healing process on the bone-tendon graft on the bone tunnel. This layer will eventually arrange the fibers that are perpendicular to each other to resemble Sharpey's fiber. The existence of sharpey's fiber determines the pullout strength of ACL reconstruction. This study was a true experimental study that aimed to determine the difference in the thickness of collagen fiber or sharpey's fiber in bone-tendon graft interfaces.
after ACL reconstruction with intravenous injection of BM-SCs and VEGF. The evaluation was performed in the third and sixth weeks after reconstruction assumed that there will be a process of increasing osteoblast cells, cholesterol and fibroblasts and blood vessels in the third week. While in the sixth week, the cells will multiply and mature. Thus, the relationship between bone-tendon graft will be stronger. It is indicated by the formation of sharpey's fiber seen along the tendon associated with bone (Rodeo et al., 1993; Liu et al., 1997)

Bone Marrow-derived Mesenchymal Stem Cells (BM-SCs) are multipotent stem cells that can be used as cell sources for tissue repair and cell therapy engineering (Griffin et al., 2010). The provision of growth factor VEGF has been shown to increase vascularization and improve the quality of fibroblast tissue integration between bone-tendon graft (Zhang et al., 2003). In this study, the result of comparative analysis using independent t-test showed significant increase of collagen fiber or sharpey's fiber thickness in ACL reconstruction treatment group with injection of BM-SCs and VEGF intratunnel compared with control group both in third week observation on femur tunnel and tibia (p <0.05) and at the sixth week observation in the femoral tunnel as well as the tibia (p <0.05). There was no significant difference in term of the thickness of collagen fiber or sharpey's fiber between the sixth week treatment group and third week treatment group.

A study conducted by Ouyang et al found that in the control group without the administration of BM-SCs demonstrated the fixation between bone-tendon graft, which was indicated by reorganization of fibrous tissue on the longitudinal axis of the bone tunnel, only in the sixth week obtained a little picture of collagen fiber that resembled sharpey's fiber. In contrast, the group with intratunnel BM-SCs exhibited more perpendicular collagen fiber or sharpey's fiber. In addition, in the treatment group demonstrated proliferation of cartilage-like cells and the formation of fibrocartilage-like tissue. So this study concluded that the administration of BM-SCs in bone tunnel can accelerate the healing of bone-tendon graft in bone tunnel (Ouyang 2004).

Research on the use of growth factor to accelerate the healing of bone tunnel has been done. Research conducted by Ma et al using various doses of rhBMP-2 in ACL reconstruction mode in rabbits has concluded that the formation of new bone and integration to tendon graft was influenced by the dose of rhBMP-2 (Ma et al., 2007). While research conducted by Martinek et al has concluded that BMP-2 significantly increased the integration of semitendinosus tendon graft in bone tunnel after ACL reconstruction of rabbits (Martinek et al., 2002). Research conducted by Yoshikawa et al using VEGF as an additional biological material after ACL reconstruction of sheep. There was a significantly greater angiogenesis formation in the tunnel graft in the treatment group than in the control group (Yoshikawa et al., 2006).

Research conducted by Ferdiasis et al on ACL reconstructed models treated by BM-SCs
and VEGF intraarticular showed that there was no significant difference between treatment group and control group at week 3 evaluation. Significant differences between the control group and the treatment group occurred at the sixth-week evaluation. This indirectly indicates that there is an acceleration to the integration process between bone with tendon graft (Ferdiansis, 2014).

In this study, there was a significant difference in the thickness of collagen fiber or Sharpey’s fiber significantly in both the femoral tunnel and the tibia tunnel in the third and sixth-week observations. This result is consistent with the research conducted by Faridyan et al on the ACL reconstruction model which is treated intravenously by BM-SCs and VEGF. The study showed significant differences in the mechanical ultimate tension strength increase between treatment groups compared with the control group in both the third-week observation and the observation of the sixth week (Faridyan, 2015). In this study, no marking was conducted on BM-SCs, so it can not be proven whether the accelerated growth is due to the given BM-SCs or host-derived cells.

**CONCLUSION**

There is an effect of injection of BM-SCs and VEGF intratunnel after ACL reconstruction characterized by the histologic picture of increased thickness of collagen fiber or Sharpey's fiber network that is directly proportional to pullout strength.

**REFERENCES**


Faridyan, BV, 2015. At the Biomechanics Test Tendon Graft Model-Bone Tunnel Post-Reconstruction of anterior cruciate ligament with allogeneic Giving Bone Marrow Mesenchymal Stem Cells (BM-SCs) and Vascular Endothelial Growth Factor (VEGF) Intratunnel. Airlangga University.


Ratajczak, MZ et al., 2007. A Hypothesis For An Embryonic Origin of Pluripotent Oct-4 + Stem Cells In Adult Bone Marrow And Other Tissues. *Leukemia*, pp.860-867.


